170x120_Matthias_Krings

Dr. Matthias Krings

Background

Matthias Krings is a founding Partner of Catenion who lives in Munich, Germany. Matthias became a consultant in 1999 at Mercer Management Consulting and later joined a strategy consulting boutique, Theron. In 2003, he co-founded Catenion.

Matthias has worked for European and global client organisations in Pharma, MedTech and Biotech strategy with a particular focus on R&D portfolio management. He has co-developed and applied specialised approaches and tools to assess and mitigate the technical and scientific risks of pharmaceutical and medical device R&D projects, and has linked these methods and tools to portfolio-level decision-making and corporate strategy. Matthias continuously helps clients master Catenion’s consulting approaches and embed them into management routines.

Since 2007 Matthias has headed the executive training and education unit of Catenion, The Catenion Academy, with the goal of significantly improving the way clients manage R&D, value assets, develop project teams and corporate strategies in Pharma, MedTech and Biotech.

In private, Matthias enjoys a variety of music, gardening, cooking, and water sports and is interested in human evolution and evolutionary psychology.

Education

Before commencing his studies, Matthias lived and worked in Florida for a year. He holds a diploma and a doctorate degree in biology from the Ludwig-Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. While in Academia, Matthias made significant scientific contributions to the field of human evolution. Matthias’ and his fellow researchers’ analysis of the first-ever DNA sequence from the Neanderthal type-specimen in 1997 continues to be one of the most frequently cited papers in the field of evolution. This study was a major breakthrough and paved the way for further studies on Neanderthal DNA. Recent technological advances have led to the retrieval of entire nuclear genomes of Neanderthals and other pleistocene hominins by Matthias’ former colleagues. It is now established that there was a limited degree of interbreeding between modern humans, Neanderthals and the recently identified group of Denisovans. 

Expertise

  • Corporate and R&D strategy development
  • Portfolio Management in Pharma and Medical Devices
  • Organisational development
  • Change management
  • R&D asset valuation
  • R&D organisation & process design
  • Due diligences in licensing & M&A context
  • Technology and research rtrategy
  • Knowledge and Innovation Management
  • Diagnostics / Pharmacodiagnostics
  • Biotech business modelling
  • Post-merger integration
  • Launch management

Published Work

Matthias co–authored Catenion’s Commentaries “Elements of Winning Strategies in R&D” and “Recombinant Portfolio Management — Recognising and Enabling Innovation”. They are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high–profile issues for the industry.